Related Experiment Video
Updated: Aug 20, 2026

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
Published on: November 11, 2016
The evolution of iPSC-based cell therapy across autologous and allogeneic pathways
Anmin Wang1, Yunpei Zhang1, Hongkui Deng2
1Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Biology, University of California, Los Angeles, CA 90095, USA.
None:
Induced pluripotent stem cell (iPSC)-based treatments have revolutionized regenerative medicine, yielding patient-specific renewable cells without raising ethical concerns related to the use of embryonic stem cells. In two decades, iPSC therapies have advanced from basic research to clinical trials and official approvals. Early research focused on autologous transplantation, exemplified by the 2014 retinal pigment epithelium (RPE) graft. Yet, personalized production obstacles prompted allogeneic schemes relying on HLA cell banks and immunomodified donor cells. Meanwhile, innovations such as chemical reprogramming have revitalized autologous strategies. Today, autologous and allogeneic iPSC therapies complement each other for distinct clinical demands. This review traces key field milestones and analyzes prospects and hurdles for next-generation iPSC therapies.
More Related Videos
Related Concept Videos
iPS Cell Differentiation
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic cells are...
EPS and iPS Cells in Disease Research
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Somatic to iPS Cell Reprogramming

